GAINESVILLE -
Details of the platform presentation are as follows
Title: TransportNPC: Open Phase 3 global trial of intravenous hydroxy-propyl-beta-cyclodextrin in patients with Niemann-Pick disease type C1
Presenter: Dr.
Session: Clinical Applications
Date and Time:
About WORLDSymposium
WORLDSymposium is an annual research conference dedicated to lysosomal diseases. WORLD is an acronym that stands for We're
About
Safe Harbor Statement
This press release contains 'forward-looking statements' about the company's current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as 'anticipates,' 'believes' and 'expects' or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the
Contact:
Tel: (833) 475-8247
Email: CYTH@jtcir.com
(C) 2023 Electronic News Publishing, source